Q2 Earnings Forecast for Prothena Issued By Zacks Research

Prothena Co. plc (NASDAQ:PRTA) – Investment analysts at Zacks Research lifted their Q2 2025 EPS estimates for shares of Prothena in a report issued on Monday, January 27th. Zacks Research analyst E. Bagri now anticipates that the biotechnology company will post earnings of ($1.36) per share for the quarter, up from their previous estimate of ($1.38). The consensus estimate for Prothena’s current full-year earnings is ($2.24) per share. Zacks Research also issued estimates for Prothena’s Q4 2025 earnings at $0.53 EPS, FY2025 earnings at ($3.49) EPS, Q1 2026 earnings at ($1.41) EPS, Q2 2026 earnings at ($1.13) EPS, Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.33) EPS and FY2026 earnings at ($3.28) EPS.

A number of other research firms have also recently issued reports on PRTA. StockNews.com cut Prothena from a “hold” rating to a “sell” rating in a research report on Tuesday, November 19th. Bank of America cut their price target on Prothena from $26.00 to $22.00 and set a “neutral” rating for the company in a report on Thursday, December 19th. HC Wainwright reiterated a “buy” rating and issued a $48.00 price objective (down from $84.00) on shares of Prothena in a report on Friday, December 20th. Finally, Chardan Capital assumed coverage on shares of Prothena in a report on Friday, December 20th. They set a “buy” rating and a $40.00 target price for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $46.50.

Prothena Trading Down 3.2 %

NASDAQ:PRTA opened at $14.23 on Thursday. The firm has a fifty day simple moving average of $14.43 and a 200 day simple moving average of $17.74. Prothena has a 1-year low of $11.70 and a 1-year high of $31.03. The stock has a market capitalization of $765.72 million, a PE ratio of -5.74 and a beta of 0.10.

Prothena (NASDAQ:PRTA) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.18) by $0.08. Prothena had a negative net margin of 98.86% and a negative return on equity of 24.19%. The business had revenue of $0.97 million during the quarter, compared to analysts’ expectations of $1.22 million. During the same quarter in the prior year, the company posted $0.38 earnings per share. The firm’s revenue was down 98.9% on a year-over-year basis.

Institutional Trading of Prothena

Several hedge funds and other institutional investors have recently made changes to their positions in PRTA. Barclays PLC boosted its position in Prothena by 110.2% during the 3rd quarter. Barclays PLC now owns 95,222 shares of the biotechnology company’s stock worth $1,592,000 after buying an additional 49,916 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Prothena by 1,122.9% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 526,748 shares of the biotechnology company’s stock worth $8,812,000 after purchasing an additional 483,673 shares during the period. Duncan Williams Asset Management LLC grew its stake in shares of Prothena by 41.9% in the fourth quarter. Duncan Williams Asset Management LLC now owns 69,199 shares of the biotechnology company’s stock worth $958,000 after purchasing an additional 20,450 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Prothena by 14.8% in the third quarter. Wellington Management Group LLP now owns 4,178,788 shares of the biotechnology company’s stock worth $69,911,000 after purchasing an additional 539,359 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. acquired a new stake in Prothena in the fourth quarter valued at $724,000. 97.08% of the stock is currently owned by institutional investors.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.